Physician profile
Mark C Stewart
NPI 1205805579
$1,078.73
in general payments reported to CMS, 2019-2025
13 companies · $54.28 in 2025
The $54.28 reported for 2025 was less than what a typical Neuromusculoskeletal Medicine, Sports Medicine provider received nationally (typical 2025 total: $125).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $499 · 2020: $54.73 · 2021: $93.94 · 2022: $163 · 2023: $184 · 2024: $30.10 · 2025: $54.28.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $268.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $268.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $492.07 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $107.49 | 2022-2023 | Seglentis |
| Medtronic, INC. | $85.16 | 2021-2023 | Zevo Anterior Cervical Plate System |
| Heron Therapeutics, INC. | $72.09 | 2021-2023 | Zynrelef |
| Depuy Synthes Sales INC. | $70.79 | 2022 | |
| Orthofix Medical, INC. | $69.01 | 2019-2024 | Physio-Stim |
| Si-Bone, INC. | $60.86 | 2020-2021 | |
| Bioventus LLC | $33.62 | 2025 | Gelsyn-3 |
| Fidia Pharma USA INC. | $22.86 | 2023 | Triluron, Hymovis |
| Vertex Pharmaceuticals Incorporated | $20.66 | 2025 | |
| Amgen INC. | $17.90 | 2021 | |
| Theragen, INC. | $15.31 | 2022 | |
| Zimmer Biomet Holdings, INC. | $10.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Stewart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.